Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Completed · Phase 3

Conditions studied: Seborrheic Dermatitis

In brief

This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.

Key facts

Study ID

NCT04973228

Run by

Arcutis Biotherapeutics, Inc.

People needed

457

Starts

2021-07-08

Expected to finish

2022-04-06

Last updated by the study team

2024-03-12

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arcutis Biotherapeutics Clinical Site 45 — Encinitas, California, United States
• Arcutis Biotherapeutics Clinical Site 46 — San Diego, California, United States
• Arcutis Biotherapeutics Clinical Site 64 — San Diego, California, United States
• Arcutis Biotherapeutics Clinical Site 21 — Santa Monica, California, United States
• Arcutis Biotherapeutics Clinical Site 42 — Coral Gables, Florida, United States
• Arcutis Biotherapeutics Clinical Site 57 — Delray Beach, Florida, United States
• Arcutis Biotherapeutics Clinical Site 33 — Largo, Florida, United States
• Arcutis Biotherapeutics Clinical Site 31 — North Miami Beach, Florida, United States
• Arcutis Biotherapeutics Clinical Site 65 — Sanford, Florida, United States
• Arcutis Biotherapeutics Clinical Site 12 — Tampa, Florida, United States
• Arcutis Biotherapeutics Clinical Site 10 — Rolling Meadows, Illinois, United States
• Arcutis Biotherapeutics Clinical Site 03 — Indianapolis, Indiana, United States
• Arcutis Biotherapeutics Clinical Site 22 — Plainfield, Indiana, United States
• Arcutis Biotherapeutics Clinical Site 15 — Louisville, Kentucky, United States
• Arcutis Biotherapeutics Clinical Site 04 — Lake Charles, Louisiana, United States
• Arcutis Biotherapeutics Clinical Site 02 — Rockville, Maryland, United States
• Arcutis Biotherapeutics Clinical Site 28 — Rockville, Maryland, United States
• Arcutis Biotherapeutics Clinical Site 40 — Clinton Township, Michigan, United States
• Arcutis Biotherapeutics Clinical Site 20 — Detroit, Michigan, United States
• Arcutis Biotherapeutics Clinical Site 14 — Fridley, Minnesota, United States
• Arcutis Biotherapeutics Clinical Site 44 — Saint Joseph, Missouri, United States
• Arcutis Biotherapeutics Clinical Site 19 — Reno, Nevada, United States
• Arcutis Biotherapeutics Clinical Site 34 — East Windsor, New Jersey, United States
• Arcutis Biotherapeutics Clinical Site 66 — New York, New York, United States
• Arcutis Biotherapeutics Clinical Site 01 — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.